Twelve patients with relapsed CD20+ B-cell non-Hodgkin’s lymphoma (B-NHL) were enrolled in a phase I study of rituximab; 4 received rituximab 250 mg/m2 and 8 received rituximab 375 mg/m2 once weekly for 4 weeks. Grade 1 or 2 infusion-related toxicity was observed. Of the 11 eligible patients, 2 achieved complete responses and 5 achieved partial responses. The elimination half-life (T1/2) of rituximab was 445 ± 361 hours, and serum rituximab levels were detectable at 3 months. There after, 90 relapse patients with indolent B-NHL or mantle cell lymphoma (MCL) were enrolled in a phase II study and treated with rituximab at 375 mg/m2 per infusion in 4 weekly infusions. Sixteen patients were ineligible in protocol compatible analyses. The overall response rates (ORR) in indolent B-NHL and MCL were 61% (37 of 61 patients) and 46% (6 of 13 patients), respectively. Factors affecting response and progression-free survival (PFS) were analyzed for 77 patients whose histopathology was centrally confirmed as indolent B-NHL or MCL. The ORR in patients receiving 1 prior chemotherapy regimen was higher than the ORR in those receiving ≥ 2 regimens (P < .05). The median PFS was shorter in MCL patients, in those with extranodal disease, and in those receiving ≥2 prior chemotherapy regimens (P < .01). The PFS of patients with higher serum rituximab levels (≥70 μxg/mL) immediately before the third infusion was longer than that of other patients (P < .01). Several pretreatment factors and serum rituximab levels are useful for predicting the efficacy of rituximab monotherapy. Rituximab re-treatment was well tolerated in 13 patients with no grade 3 or 4 nonhematological toxicities. A partial response was observed in 5 patients (38%), and the median PFS after re-treatment was 5.1 months. In conclusion, rituximab is a highly effective agent in relapsed indolent and aggressive B-NHL and MCL and has acceptable toxicities.Int J Hematol. 2002;76:411-419.
This is a preview of subscription content, log in to check access.
Buy single article
Instant access to the full article PDF.
Price includes VAT for USA
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
This is the net price. Taxes to be calculated in checkout.
Horning SJ. Natural history of and therapy for the indolent non-Hodgkin’s lymphomas.Semin Oncol. 1993; 20(suppl 5): 75–88.
Bierman PJ, Vose JM, Anderson JR, et al. High-dose therapy with autologous hematopoietic rescue for follicular low-grade non-Hodgkin’s lymphoma.J Clin Oncol. 1997; 15: 445–450.
Reff ME, Carner K, Chambers KS, et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20.Blood. 1994; 83: 435–445.
Maloney DG, Liles TM, Czerwinski DK, et al. Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma.Blood. 1994; 84: 2457–2466.
Clynes RA, Towers TL, Presta LG, Ravetch JV. Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets.Nat Med. 2000; 6: 443–446.
Maloney DG, Grillo-Lopez AJ, Bodkin DJ, et al. IDEC-C2B8 results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin’s lymphoma.J Clin Oncol. 1997; 15: 3266–3274.
Maloney DG, Grillo-Lopez AJ, White CA, et al. IDEC-C2B8 (rit-uximab) anti-CD20 antibody therapy in patients with relapsed low-grade non-Hodgkin’s lymphoma.Blood. 1997; 90: 2188–2195.
McLaughlin P, Grillo-Lopez AJ, Link BK, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.J Clin Oncol. 1998; 16: 2825–2833.
Tobinai K, Kobayashi Y, Narabayashi M et al. Feasibility and phar-macokinetic study of a chimeric anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab) in relapsed B-cell lymphoma.Ann Oncol. 1998; 9: 527–534.
Igarashi T, Kobayashi Y, Ogura M, et al. Factors affecting toxicity, response and progression-free survival in relapsed patients with indolent B-cell lymphoma and mantle cell lymphoma treated with rituximab: a Japanese phase II study.Ann Oncol. 2002; 13: 928–943.
Tobinai K. Clinical trials of a mouse-human chimeric anti-CD20 monoclonal antibody (rituximab) for B cell non-Hodgkin’s lymphoma in Japan.Cancer Chemother Phamacol. 2001; 48(suppl 1): S85-S90.
Harris NL, Jaffe ES, Stein H, et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group.Blood. 1994; 84: 1361–1392.
Igarashi T, Ohtsu T, Fujii H, et al. Re-treatment of relapsed indolent B-cell lymphoma with rituximab.Int J Hematol. 2001; 73: 213–221.
Coiffier B, Haioun C, Ketterer N, et al. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study.Blood. 1998; 92: 1927–1932.
Foran JM, Rohatiner AZS, Cunningham D, et al. European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma.J Clin Oncol. 2000; 18: 317–324.
Davis TA, Grillo-Lopez AJ, White CA, et al. Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin’s lymphoma: safety and efficacy of re-treatment.J Clin Oncol. 2000; 18: 3135–3143.
Schmitz K, Brugger W,Weiss B, Kaiserling E, Kanz L. Clonal selection of CD20-negative non-Hodgkin’s lymphoma cells after treatment with anti-CD20 antibody rituximab [letter].Br J Haematol. 1999; 106: 571–572.
Davis TA, Czerwinski DK, Levy R. Therapy of B-cell lymphoma with anti-CD20 antibodies can result in the loss of CD20 antigen expression.Clin Cancer Res. 1999; 5: 611–615.
Micallef INM, Kirk A, Norton A, Foran JM, Rohatiner AZS, Lister TA. Peripheral T-cell lymphoma following rituximab therapy for B-cell lymphoma [letter].Blood. 1999; 93: 2427–2428.
Kinoshita T, Nagai H, Murate T, Saito H. CD20-negative relapse in B-cell lymphoma after treatment with rituximab [letter].J Clin Oncol. 1998; 16: 3916.
Igarashi T, Itoh K, Kobayashi Y, et al. Phase II and pharmacokinetic study of rituximab with eight weekly infusions in relapsed aggressive B-cell non-Hodgkin’s lymphoma (B-NHL).Proc Am Soc Clin Oncol. 2002; 21: 286a.
Cheson BD, Horning SJ, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin’s lym-phomas.J Clin Oncol. 1999; 17: 1244–1253.
Czuczman MS, Grillo-Lopez AJ, White CA, et al. Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy.J Clin Oncol. 1999; 17: 268–276.
Vose JM, Link BK, Grossbard ML, et al. Phase II study of rituximab in combination with CHOP chemotherapy in patients with previously untreated, aggressive non-Hodgkin’s lymphoma.J Clin Oncol. 2001; 19: 389–397.
Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rit- uximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.N Engl J Med. 2002; 346: 235–242.
Witzig TE, White CA,Wiseman GA, et al. Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20+ B-cell non-Hodgkin’s lymphoma.J Clin Oncol. 1999; 17: 3793–3803.
Witzig TE, Gordon LI, Cabanillas F, et al. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioim-munotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin’s lymphoma.J Clin Oncol. 2002; 20: 2453–2463.
Kaminski MS, Zelenetz AD, Press OW, et al. Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin’s lymphomas.J Clin Oncol. 2001; 19: 3918–3928.
Kreitman RJ, Wilson WH, Bergeron K, et al. Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy cell leukemia.N Engl J Med. 2001; 345: 241–247.
About this article
Cite this article
Tobinai, K. Monoclonal Antibody Therapy for B-Cell Lymphoma: Clinical Trials of an Anti-CD20 Monoclonal Antibody for B-Cell Lymphoma in Japan. Int J Hematol 76, 411–419 (2002). https://doi.org/10.1007/BF02982806
- Monoclonal antibody therapy
- B-cell lymphoma
- Chimeric antibody